Home › Compare › JRHIF vs ABBV
JRHIF yields 4.84% · ABBV yields 3.06%● Live data
📍 JRHIF pulled ahead of the other in Year 2
Combined, JRHIF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of JRHIF + ABBV for your $10,000?
Daiwa Securities Living Investment Corporation (hereinafter referred to as "the Investment Corporation") is listed on the Tokyo Stock Exchange in June 2006 (stock code: 8986) and is located in the metropolitan area and major cities throughout Japan (Sapporo City, Sendai City) It is a rental apartment specialized REIT (REIT) that invests in rental apartments in Nagoya City, Osaka City, Fukuoka City, etc. After the acquisition of Prospect Reit Investment Corporation in July 2010, the Investment Corporation will actively replace properties (acquisition of new properties) with the management ability of the asset management company Daiwa Real Estate Asset Management Co., Ltd. And the sale of existing properties), drastic operation reinforcement (achievement of high occupancy rate), various cost reductions, etc., and we have achieved improvement in distribution. In December 2015, Daiwa Securities Group Inc. (hereinafter referred to as "Daiwa Securities Group Inc.") will acquire additional shares of the asset management company, and the Investment Corporation will bring Daiwa Securities Group Inc. as a new sponsor have become. The Investment Corporation will use its support based on the sponsor-support agreement concluded between the asset management company and the Daiwa Securities Group headquarters to aim for sustainable and stable growth. The Investment Corporation will continue to aim to maximize the profits of its investors. We would like to ask all investors for their continued support and rewards.
Full JRHIF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.